{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"30.6","upperLimit":"48.6","value":"39.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"122"}],"units":"Participants"}],"description":"IRC assessed CBR per 2016 IMWG criteria: Percentage of participants with a confirmed minimal response (MR) or better (PR, VGPR, CR or sCR) before confirmed disease progression or initiating new MM treatment. Minimal response (MR): \\>= 25% but \\< 49% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 50-89%. Partial response (PR): \\>= 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \\>= 90% or to \\< 200 mg per 24 hours; Very good partial response (VGPR): Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \\< 100 mg per 24 hours; Complete response (CR): Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \\<= 5% plasma cells in bone marrow; or stringent complete response (sCR): CR as defined+Normal free light chain (FLC) ratio+Absence of clonal cells by immunohistochemistry).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who previously had received more than 3 anti-MM regimens and had penta-exposed, triple class-refractory MM (i.e. previously treated with lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab, and refractory to prior treatment with glucocorticoids, an IMiD, a PI, and the anti-CD38 mAb daratumumab) received, selinexor 80 mg PO plus low-dose dexamethasone 20 mg Sd twice-weekly on Days 1 and 3 until disease progression, death, or unacceptable toxicity (maximum duration of approximately 17 months).","id":"OG000","title":"Part 2"}],"paramType":"NUMBER","populationDescription":"mITT population consisted of Part 2 participants with penta-refractory MM who met all eligibility criteria and received at least one dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Baseline up to a maximum of 17 months","title":"Part 2: Percentage of Participants With Clinical Benefit Rate (CBR) Per IMWG as Assessed by IRC","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}